Obtenga las últimas noticias sobre las acciones de DBV Technologies con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de DBVT

Últimas noticias sobre

DBV TECHNOLOGIES SA-SPON ADR

DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Stock,Market,Graph,Trading,Analysis,Investment,Financial,,Stock,Exchange,Financial

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABSI

ALLT

ALUR

ASNS

AXDX

DBVT

DEVS

FNGR

GRAL

LRHC

LUCY

PLRZ

UBER

WBUY

XHLD

XTKG

Las acciones de Everus Construction Group suben un 14,7 % tras superar expectativas de ganancias y ventas en el primer trimestre.

Acciones de Everus Construction (ECG) se disparan un 15%; Aquí están 20 acciones que se mueven en premercado

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

DBV TECHNOLOGIES SA by DBV Technologies SA

Press Releases

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025

DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

DBV Technologies Announces Resignation of Board Member

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

DBV Technologies Reports Third Quarter 2025 Financial Results

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

PARIS:DBV

ADC Therapeutics

Akebia Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

CytomX Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

Immuneering Corporation - Class A Common Stock

Immuneering

Jade Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Keros Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

NovaBridge Biosciences - American Depositary Shares

NovaBridge Biosciences

Neurogene

Ocugen

Organogenesis Holdings

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

Comments

DBV Technologies Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL